Abstract
Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have